Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

RAET1E activates adverse response. 1 / 1

| 1

➶

eidos

"We then transiently knocked down the expression of Raet1e via siRNA inUbr5 - / -4 T1 tumor ( Figure 5b ) , which , when implanted in mice , caused a partial reversal of the inhibited growth of the parental tumor ( Figure 5c ) , but did not alter thein vitro growth rates ( Figure S1E ) , suggesting that higher Raet1e expression may mediate an adverse response against the tumor and that UBR5 deficiency in tumor cells may generate immunogens that attract anti-tumor responses.Upregulated proteins inUbr5 - / -4 T1 tumor.Potential immunogens and interacting partners controlled by UBR5 ."

32363114

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...